All terms

    ICS Medical Advisory

    CISA's official vulnerability advisories for medical devices, the public record of disclosed device cybersecurity issues, indexed as ICSMA-YY-DDD-NN.

    Reviewed by Christian Espinosa, Founder, Blue Goat CyberLast reviewed June 20, 2026

    Definition

    ICS Medical Advisories are CISA public vulnerability advisories for healthcare products. They commonly identify affected versions, vulnerabilities, CVEs, severity information, mitigations and reporting acknowledgments. FDA or Health-ISAC involvement and a manufacturer disclosure timeline are not guaranteed elements of every advisory.
    What the regulation says
    CISA advisories support coordinated vulnerability response. Section 524B(b)(1) requires applicable cyber-device sponsors to provide CVD and related procedures, but does not mandate publication of an ICSMA or use of a particular sharing organization. FDA guidance is the February 2026 edition.

    What this means in practice

    Use ICSMAs as inputs to vulnerability assessment, remediation and communication. Separately assess applicable medical device reporting, corrections/removals and customer-notification obligations. An ICSMA alone does not mandate board reporting or Form FDA 3500A submission.

    Examples

    • Illustrative: A hospital cybersecurity team reviewed a recent ICSMA regarding a widely used imaging system to understand the vulnerability's impact and implement recommended mitigations before the manufacturer released a patch.
    • Illustrative: During a procurement review, an HDO's risk management committee identified an ICSMA associated with a vendor's infusion pump, prompting further questions about the manufacturer's remediation plan and long-term security commitments.
    • Illustrative: A MedTech manufacturer received an ICSMA designation for a discovered flaw in their connected diagnostic device, triggering an immediate internal investigation, customer notification process, and accelerated patch development.
    Common pitfalls
    • •Discovering ICSMA process for the first time during an incident, pre-establish CISA and FDA contacts and run a tabletop.
    • •Treating ICSMAs as marketing damage to be minimized, incomplete or evasive advisories destroy trust with hospital customers far more than the underlying vulnerability.
    • •Ignoring competitor ICSMAs, they are the best public signal of what credible attacks against your product class look like.

    Frequently asked questions

    ICS Medical Advisories (ICSMAs) are the CISA advisory series specifically for medical devices, while ICS-Advisories (ICSAs) cover the broader industrial control systems sector; both follow the same general advisory structure describing affected products, CVE identifiers and CVSS scores, risk evaluation, and mitigations, but ICSMAs are coordinated closely with FDA's Center for Devices and Radiological Health given the patient-safety implications specific to medical devices.
    Grouped by theme
    Cited by

    Where this term appears across MedTech Terms.

    Sources

    5 sources

    Sources support the definition or relevant regulatory context, not necessarily every claim on this page. Each is graded against our source-tier hierarchy so you can see what rests on binding law versus commentary.

    Official-source claim check:

    CISA publishes ICSMAs describing healthcare-product vulnerabilities and mitigations; publication does not itself trigger FDA reporting.

    Partial review: verified corrections are applied, but this is not a full accuracy certification. The last full review date is unchanged.

    Remaining verification limits
    • Secondary regulatory, standards-clause, market-prevalence or procurement claims were not fully substantiated by accessible original text.
    Tier 2Regulator guidance and consensus· 4Tier 4Trade press and expert commentary· 1
    Link health: 3 verified 2 unchecked· last checked 2026-06-20
    CISA·2MDCG·1HSCC·1FDA·1
    1. 1
      CISA Coordinated Vulnerability Disclosure Process
      Tier 2 Verified
      CISAcisa.gov
    2. 2
      MDCG Cybersecurity Guidance
      Tier 2 Verified
      MDCGhealth.ec.europa.eu
    3. 3
      HSCC - Health Sector Coordinating Council
      Tier 4 Verified
      HSCChealthsectorcouncil.org
    4. 4
      CISA Orthanc ICSMA
      Tier 2 Unchecked
      CISAcisa.gov
    5. 5
      FDA final guidance, February 3, 2026
      Tier 2 Unchecked
      FDAfda.gov

    Inline markers like [1] jump to the matching reference above.